Medea Inc Awarded $190M for diagnostic tests for non-prescription home use for the qualitative detection of protein antigen

post-img

Medea Inc.,* Pleasanton, California, was awarded a $190,100,000 firm-fixed-price contract for diagnostic tests for non-prescription home use for the qualitative detection of protein antigen from the novel coronavirus SARS-CoV-2. Bids were solicited via the internet with three received. Work will be performed in Pleasanton, California, with an estimated completion date of Jan. 24, 2022. Fiscal 2022 CARES Act funds in the amount of $190,100,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-22-C-0005). (Awarded Jan. 9, 2022)

Medea Inc. is located in Pleasanton, CA, United States, and is part of the Machinery, Equipment, and Supplies Merchant Wholesalers Industry. Medea Inc. has 14 total employees across all of its locations and generates $51.37 million in sales (USD). (Sales figure is estimated). (www.dnb.com)